Hence, for Patient #1, although sorafenib and olaparib were chosen chemotherapies due to their advantages in advanced platinum-sensitive KRAS-mutant NSCLC [66,67,68,69] for our TEVA model, their standalone usage bore no significant results. This evidence concerns the gene KRAS and non-small cell lung carcinoma.